UCT-01097 is under clinical development by 1200 Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how UCT-01097’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
UCT-01097 is under development for the treatment of advanced solid tumors. It is administered by oral route. The drug candidate act by targeting kinase receptors.
1200 Pharma overview
1200 Pharma, is a developer of novel oncology therapeutics utilizing breakthrough medicinal chemistry. The company is headquartered in United States.
For a complete picture of UCT-01097’s drug-specific PTSR and LoA scores, buy the report here.